Dwight Evans isn't trending on Google News right now. The Bluesky chatter about him this week is about a 1976 Papa Gino's promotional glass featuring a different Dwight Evans, the Red Sox outfielder. That's the level of public scrutiny the Philadelphia congressman is operating under. Which makes this a good time to look at what he's actually been doing with his brokerage account.
Five disclosed trades in 90 days. All sales. Zero buys. And a 30-day alpha record that reads like a cautionary tale printed in a Wharton intro course under the heading "What Not To Do."
Per the disclosure record at Blind Trust, Evans has been selling steadily since late March. The sales span four sectors: semiconductors, power infrastructure, life sciences equipment, and cell towers. The market, in many of these cases, moved up after he got out. That's the story. That's the whole story.
The Sell-Off, Dated
Start with March 24. Evans disclosed a sale of Micron Technology (MU) in the $15,000-$50,000 range. That's the largest single disclosed position in this 90-day window. Micron's 30-day alpha after the sale date: negative 14.1 percent versus the S&P 500. He sold before a significant underperformance. His one genuinely well-timed exit in the batch.
Then came May 7, when three sales dropped in the same filing window. He sold Intel (INTC), Quanta Services (PWR), and Thermo Fisher Scientific (TMO), all in the $1,000-$15,000 range. The 30-day alpha on those three: negative 1.5 percent, negative 7.7 percent, and negative 7.8 percent, respectively. Selling Intel before it dropped further might look okay in isolation. Selling Quanta Services and Thermo Fisher before they each outperformed the index by nearly eight points is a different matter.
May 11 added a sale of American Tower (AMT), also $1,000-$15,000. Thirty-day alpha: flat, essentially zero. A wash.
The full scored sample across all eight of Evans's evaluated trades: zero positive alpha outcomes out of eight. Mean 30-day alpha: negative 5.7 percent. Every single scored trade went the wrong direction relative to the market after he moved. The best trade in the record is the AMT sale, which broke even. That's the winner.
The Thermo Fisher Angle
One of these trades carries a wrinkle worth naming directly. Thermo Fisher Scientific operates in life sciences and laboratory equipment. Evans sits on the House Committee on Ways and Means, including its Health subcommittee. Ways and Means Health has jurisdiction over Medicare, Medicaid, and the tax treatment of healthcare spending. It does not regulate medical device companies or lab equipment manufacturers in the way, say, Energy and Commerce does. But Thermo Fisher's business touches federal healthcare policy at enough edges that the overlap is worth flagging.
The Blind Trust data flags the TMO sale as carrying a committee overlap on Healthcare. Evans sold TMO on May 7. The 30-day return after that sale was negative 7.8 percent alpha versus the S&P. He sold before the stock went up relative to the index. The committee overlap is real. The alpha outcome was bad. Both of those things are true simultaneously.
Members are required to disclose trades within 45 days of execution. They are not required to recuse themselves from relevant committee work, divest from holdings, or explain the timing. That's the rule. Yes, really.
What He Voted On While Selling
On May 20, Evans voted Yea on four bills that passed the House floor, including the American Access to Banking Act (H.R. 4544) and the Community Bank Deposit Access Act of 2025 (H.R. 5317). Both bills touch bank regulation and deposit access. Neither sits in Ways and Means jurisdiction. The Financial Services Committee owns that turf. Evans's Yes votes on both are floor votes, nothing more. No committee angle, no oversight role, no conflict framing to build here.
He voted Nay on the Veterans 2nd Amendment Protection Act and the Sharri Briley and Eric Edmundson Veterans Benefits Expansion Act on May 21, both of which passed without him. On June 11, he voted Nay on a FISA surveillance reauthorization bill that failed. His vote was on the winning side of that one, at least.
The vote-trade overlap table in the Blind Trust data is empty. No flagged timing collisions between his disclosed trades and relevant committee-level votes. The trades exist in a separate column from the legislative calendar, and they don't visibly intersect.
The Alpha Record in Full
Eight trades scored. Eight negative alpha outcomes. The best result breaks even. The worst, that Micron sale in March, actually looks like the one sharp move: he sold MU before it dropped 14 points below the index. But the MU sale is an outlier in the wrong direction from what you'd hope, because the next four trades all involved selling stocks that then outperformed.
To be direct about what alpha means here: it's the 30-day excess return of the stock versus the S&P 500 after the trade date. A negative alpha on a sale means the stock went up more than the market (or down less), which means selling was the wrong call relative to holding. It does not mean Evans lost money. He may have locked in gains. It means, by this measure, the timing wasn't market-beating. Across eight scored trades, it never was.
There's no cherry-picking available in that number. Zero for eight is the full record, not a rough patch.
Who Is Dwight Evans, Actually
Evans represents Pennsylvania's 3rd Congressional District, anchored in Philadelphia. He's been in the House since 2016, spent decades before that in the Pennsylvania state legislature, and sits on Ways and Means, one of the more powerful committee assignments in the chamber. Ways and Means writes tax policy, oversees trade, and controls Social Security and Medicare financing. It's not a backbench posting.
The trades disclosed in the last 90 days are all on the small end of the STOCK Act disclosure ranges. The Micron sale, the largest, tops out at $50,000. These aren't whale moves. They're the kind of portfolio shuffling that looks, on its face, like ordinary personal finance. The reason to track them anyway is that the STOCK Act exists precisely because ordinary personal finance looks different when you have a seat on Ways and Means Health and you're selling a life sciences company.
That said: the alpha record doesn't suggest someone trading ahead of anything. It suggests someone whose timing has been, consistently, off.
The Receipts
Here's what the public filing record shows, stripped down:
- March 24, 2026: Sold Micron Technology (MU), $15K-$50K. Alpha: -14.1%.
- May 7, 2026: Sold Intel (INTC), $1K-$15K. Alpha: -1.5%.
- May 7, 2026: Sold Quanta Services (PWR), $1K-$15K. Alpha: -7.7%.
- May 7, 2026: Sold Thermo Fisher Scientific (TMO), $1K-$15K. Alpha: -7.8%. Committee overlap flagged.
- May 11, 2026: Sold American Tower (AMT), $1K-$15K. Alpha: 0.0%.
All sales. No buys. Mean alpha across the full eight-trade scored sample: negative 5.7 percent. The committee overlap on TMO is the one angle that earns a second look on its own terms.
What it means that a Ways and Means Health subcommittee member sold a healthcare-adjacent stock that then rose relative to the market is a question the data raises and declines to answer. The receipts are public. Make of them what you make of them.